Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06791525 · ClinicalTrials.gov registry record · Phase 4
Tirbanibulin for Pediatric Warts
A Phase 4 study of Warts Hand, sponsored by The Skin Center Dermatology Group.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06791525: Recruiting Phase 4 study of Warts Hand, sponsored by The Skin Center Dermatology Group.
NCT06791525 is a Phase 4 study of Warts Hand that is actively recruiting participants, run by The Skin Center Dermatology Group. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06791525, a Phase 4 study of Warts Hand, is actively recruiting participants, sponsored by The Skin Center Dermatology Group.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
Primary Outcome
Ful resolution of treated lesions
Conditions Studied
Interventions
- DRUG Tirbanibulin ointment 1%
Study Locations (1)
New York
- The Skin Center Dermatology Group - New City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 4 |
What NCT06791525 shows while recruiting
NCT06791525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Warts Hand appearing as the primary indexed condition, and to 1 intervention - of which Tirbanibulin ointment 1% is the first listed.
NCT06791525 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06791525 about?
NCT06791525 is a clinical study titled "Tirbanibulin for Pediatric Warts". Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5...
What is the current status of trial NCT06791525?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2025-05-01. Estimated completion is 2025-12-30.
What conditions does trial NCT06791525 study?
This clinical trial studies the following conditions: Warts Hand.
What interventions are being tested in trial NCT06791525?
The interventions under investigation include: Tirbanibulin ointment 1% (DRUG).
Who is sponsoring clinical trial NCT06791525?
This trial is sponsored by The Skin Center Dermatology Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06791525 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06791525's enrollment target sits among peer trials
10 1941st of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI